Panel Discussion: Next-Gen Nitrosamine Control – Transforming the Future of Pharma

Connect on

Panel Discussion: Next-Gen Nitrosamine Control – Transforming the Future of Pharma

Connect on

Raphael has over 20 years of pharmaceutical industry experience. He has a Ph.D. in organic chemistry from the Weizmann Institute of Science in Israel, a post-doctorate at the US Air Force Research Lab in Aberdeen Proving Ground, Maryland, and another post-doctorate at Duke University Medical Center, North Carolina. In 2003 Raphael joined the Medicinal Chemistry department at Teva Pharmaceuticals.

In 2010 he established the Chemical & Computational Toxicology group in Teva, and now he is the Senior Director of Impurity Expert in R&D Operations. Raphael's main topics of expertise are impurity and excipient qualification in drug substances and drug products. Over the past few years, he has specialized in risk assessment of nitrosamine impurities in pharmaceuticals.

Connect on

Muzaffar Khan, Senior General Manager at Laurus Labs Limited, holds a Master’s in Organic Chemistry from Osmania University and a PhD in Chemistry from JNTU-Hyderabad. Starting his career in 2000 at Dr. Reddy’s Discovery Research, he joined Laurus Labs in 2006.

He has presented extensively on mutagenic and nitrosamine impurities, including at ICH M7 Indian Roadshows with Lhasa Limited and in a 2022 international webinar with Dr. Andrew Teasdale. Khan has also served as a reviewer for leading journals, though his current role limits time for reviews.

Panel Discussion: Next-Gen Nitrosamine Control – Transforming the Future of Pharma

Connect on